MAIA Biotechnology (NYSEAMERICAN:MAIA) Trading 3.2% Higher

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) was up 3.2% on Tuesday . The stock traded as high as $2.62 and last traded at $2.57. Approximately 424,745 shares traded hands during mid-day trading, an increase of 0% from the average daily volume of 423,509 shares. The stock had previously closed at $2.49.

MAIA Biotechnology Stock Performance

The company has a market cap of $51.40 million, a price-to-earnings ratio of -1.71 and a beta of 0.41.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last released its earnings results on Thursday, March 21st. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.06). Equities analysts expect that MAIA Biotechnology, Inc. will post -1.25 earnings per share for the current fiscal year.

Insider Activity at MAIA Biotechnology

In other MAIA Biotechnology news, Director Stan Smith purchased 170,940 shares of the company’s stock in a transaction that occurred on Thursday, March 14th. The stock was purchased at an average price of $1.17 per share, with a total value of $199,999.80. Following the completion of the transaction, the director now directly owns 857,568 shares of the company’s stock, valued at approximately $1,003,354.56. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 56.97% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. FNY Investment Advisers LLC acquired a new stake in shares of MAIA Biotechnology during the third quarter worth approximately $38,000. Renaissance Technologies LLC acquired a new stake in shares of MAIA Biotechnology during the first quarter worth approximately $71,000. Citadel Advisors LLC acquired a new stake in shares of MAIA Biotechnology during the second quarter worth approximately $51,000. Bridgeway Capital Management LLC increased its holdings in shares of MAIA Biotechnology by 46.7% during the fourth quarter. Bridgeway Capital Management LLC now owns 75,700 shares of the company’s stock worth $89,000 after buying an additional 24,100 shares in the last quarter. Finally, Centric Wealth Management grew its stake in shares of MAIA Biotechnology by 60.3% during the second quarter. Centric Wealth Management now owns 64,456 shares of the company’s stock valued at $142,000 after purchasing an additional 24,250 shares during the last quarter. Institutional investors and hedge funds own 5.65% of the company’s stock.

About MAIA Biotechnology

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.